Tigecycline hydrochloride is a glycylcycline antibiotic used to treat complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections (cIAI) caused by susceptible bacteria. It exhibits broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic organisms, making it effective against multi-drug resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. It is typically reserved for cases where other antibiotics are ineffective due to resistance or intolerance. Tigecycline is administered intravenously for rapid systemic delivery. Its use requires careful monitoring due to risks of side effects, including nausea, vomiting, and increased mortality in certain infections like ventilator-associated pneumonia, as well as potential for promoting antibiotic resistance.